Brooks LAB Limited
NSE: BROOKS · Pharmaceuticals · sector
₹57.86NSE close 2026-10-26
Key numbers
Market cap₹170 cr
Price₹57.86
52w high / low₹124 / ₹36
P/E12.9xSector median 27.9x
P/B1.4xSector median 2.9x
Book value₹41.6
Dividend yield–Sector median 0.48%
ROE11.9%Sector median 11.7%
ROCE4.1%Sector median 12.3%
OPM7.0%Sector median 14.0%
Debt / equity0.06xSector median 0.16x
EV/EBITDA29.3xSector median 18.6x
Interest cover7.2x
Current ratio1.72x
Sales growth 3y+10.7%Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG0.02x
Last 12 months to Jun 2026, Consolidated. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹8 cr vs borrowings ₹7 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 7.2x in the last 12 months.
- No promoter shares are pledged.
- Operating cash flow was below net profit in 2 of the last 5 years (FY26, FY22).
- Net loss in 4 of the last 8 quarters.
- Revenue was higher than a year earlier in 1 of the last 4 quarters.
- Other income was 9% of net profit in the last 12 months.
- No dividend in the last 5 financial years.
- Price ₹57.86 on 2026-10-26: -53.2% from the 52-week high, +59.4% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹191.15 · low ₹44.53
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 21 | 21 | 23 | 26 | 23 | 17 | 20 | 23 |
| EBITDA | 2 | 2 | 2 | 3 | 3 | 1 | 1 | 2 |
| OPM % | 7.3% | 7.7% | 6.6% | 12.3% | 10.7% | 4.4% | 3.4% | 8.1% |
| Other income | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Net profit | -4 | -2 | -1 | 10 | 8 | 6 | 1 | -2 |
| EPS (₹) | -1.51 | -0.82 | -0.54 | 3.25 | 2.71 | 1.87 | 0.52 | -0.61 |
| Revenue YoY | +12.8% | -19.2% | -13.3% | -10.0% | ||||
| Profit YoY | – | – | – | -118.7% |
Consolidated figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 91 | 63 | 79 | 83 | 86 | 83 |
| EBITDA | -14 | -27 | 3 | 5 | 7 | 6 |
| Net profit | -16 | -21 | -20 | -10 | 25 | 13 |
| EPS (₹) | -7.82 | -12.57 | -7.67 | -3.72 | 8.35 | 4.49 |
| Revenue growth | -30.6% | +25.8% | +3.9% | +3.9% | -7.7% | |
| Profit growth | – | – | – | – | +548.9% | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | +10.7% | +2.1% | -7.7% |
| Net profit | – | – | +548.9% |
| EPS | – | +5.8% | – |
| Share price | – | -33.5% (2y) | -49.5% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 74 | 66 | 98 | 123 |
| Borrowings | – | 6 | 5 | 6 | 7 |
| Cash & equivalents | – | 1 | 1 | 1 | 8 |
| Total assets | – | 110 | 90 | 124 | 148 |
| Fixed assets | – | 14 | 13 | 13 | 13 |
| Capital work in progress | – | 0 | 0 | 1 | 1 |
| Investments | – | 0 | 43 | 74 | 92 |
| Receivables | – | 13 | 16 | 20 | 16 |
| Inventory | – | 11 | 10 | 9 | 11 |
| Payables | – | 23 | 15 | 14 | 11 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | -37 | -14 | -10 | 3 | 9 |
| Cash from investing | -25 | 0 | 0 | -46 | -3 |
| Cash from financing | 64 | 11 | 10 | 43 | 0 |
| Capex | 28 | 0 | 0 | 1 | 4 |
| Free cash flow | -65 | -15 | -10 | 2 | 6 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | -28.3% | -29.9% | -10.2% | 20.0% |
| ROCE % | – | -42.2% | 3.4% | 4.1% | 5.1% |
| Debtor days | – | 74 | 75 | 88 | 69 |
| Inventory days | – | 82 | 62 | 62 | 79 |
| Payable days | – | 169 | 100 | 92 | 82 |
| Cash conversion cycle (days) | – | -13 | 37 | 58 | 66 |
| Working capital days | – | -31 | 37 | 49 | 66 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 52.62% |
| FIIs | 0.04% |
| DIIs | 10.50% |
| of which Mutual funds | 9.90% |
| Public (non-institutions) | 36.84% |
| Quarter | Jan 2025 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 52.62% | 52.62% | 52.62% | 52.62% | 52.62% | 52.62% | 52.62% | 52.62% |
| Promoter group | % |
|---|---|
| Atul Ranchal | 19.24% |
| Rajesh Mahajan | 17.36% |
| Erwin Mahajan | 4.10% |
| Rajni Ranchal | 2.92% |
| Savvy Ranchal | 2.67% |
| Aryan Mahajan | 2.47% |
| Saras Gupta | 2.34% |
| Selina Ranchal | 1.52% |
| Davinder Kumari | 0.00% |
| Manmohan Lal Mahajan | 0.00% |
| Public holders above 1% | % |
|---|---|
| Quant Mutual Fund - Quant Business Cycle Fund | 9.90% |
| Saumik Ketankumar Doshi | 1.20% |
| One Up Financial Consultants Pvt Ltd | 1.02% |
11,253 shareholders. Pledged: 0.00% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| BROOKS | ₹170 cr | 12.9x | 1.4x | 11.9% | 4.1% | 7.0% | +10.7% | – |
Business segments (FY26)
| Segment | Revenue | Share | EBIT | Margin |
|---|---|---|---|---|
| b) Manufacturing | ₹83 cr | 96.7% | ₹7 cr | 8.4% |
| a) Trading | ₹3 cr | 3.3% | ₹-0 cr | -2.2% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2024-09-12 | Other | Annual General Meeting |
| 2023-09-14 | Other | Annual General Meeting |
| 2023-07-28 | Rights | Rights 1:16 @ Premium Rs 65/- |
| 2022-09-22 | Other | Annual General Meeting |
| 2021-09-21 | Other | Annual General Meeting |
| 2020-09-18 | Other | Annual General Meeting |
| 2020-02-11 | Rights | Rights 9:20 @ Premium Rs 10/- |
| 2019-09-17 | Other | Annual General Meeting |
| 2018-08-02 | Other | Annual General Meeting |
| 2017-09-20 | Other | Annual General Meeting |
| 2016-09-19 | Other | Annual General Meeting |
| 2015-09-21 | Other | Annual General Meeting |
| 2014-07-31 | Other | Annual General Meeting |
| 2013-08-29 | Other | Annual General Meeting |
| 2012-09-14 | Other | Annual General Meeting |
Documents
- Annual report FY26
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Announcements NSE filings
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | BROOKS |
| BSE code | 533543 |
| ISIN | INE650L01011 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.